Carlsmed Q1 revenue jumps 58%, company raises 2026 outlook

Carlsmed

05/05/2026 21:17

Overview

US medical technology firm's Q1 revenue rose 58% yr/yr to $16.1 mln

Gross margin improved to 77.1% from 74.9% a year ago

Company raised 2026 revenue guidance to $72 mln-$77 mln

Outlook

Carlsmed raises 2026 revenue guidance to $72 mln-$77 mln

Result Drivers

PRODUCT LAUNCHES - Co cited the first full commercial quarter for aprevo Cervical and debut of corra personalized cervical plating system as supporting growth

CLINICAL DATA - Publication of peer-reviewed study showing 74% reduction in revision rates for aprevo lumbar implants

Company press release: ID:nGNX3tHzss

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
$16.10 mln
Q1 Net Loss
$8.70 mln
Q1 Adjusted EBITDA
-$7.50 mln
Q1 Gross Margin
77.10%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Carlsmed Inc is $18.00, about 98% above its May 4 closing price of $9.09

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)